Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment optimization in multiple sclerosis.

Mark S Freedman1, David G Patry, François Grand'Maison

  • 1MS Research Clinic, University of Ottawa, Ottawa Hospital General Campus, Ottawa, Ontario, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|June 17, 2004
PubMed
Summary

Disease-modifying therapies (DMTs) help multiple sclerosis (MS) but aren't cures. New Canadian guidelines help doctors monitor MS treatment effectiveness and adjust therapies when needed for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaining biological insights through supervised data visualization.

Nature computational science·2026
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Therapeutic advances in neurological disorders·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Area of Science:

  • Neurology
  • Immunology

Background:

  • Disease-modifying therapies (DMTs) have improved multiple sclerosis (MS) management.
  • Despite DMTs, many MS patients experience ongoing disease activity.
  • Current clinical practice lacks standardized criteria for assessing DMT response and optimizing treatment.

Purpose of the Study:

  • To provide practical recommendations for assessing patient response to DMTs in MS.
  • To guide neurologists on when to modify treatment for optimal patient outcomes.
  • To establish criteria for defining optimal versus suboptimal responses to MS therapies.

Main Methods:

  • Development of recommendations by The Canadian Multiple Sclerosis Working Group.
  • Framework based on a recently published model for assessing treatment response.

Related Experiment Videos

  • Consideration of clinical monitoring of relapses, neurological progression, and MRI activity.

    • Main Results:

    • The working group developed practical recommendations for assessing MS patient status on DMTs.
    • Guidelines address monitoring relapses, neurological progression, and MRI activity.
    • Recommendations consider factors contributing to suboptimal treatment responses or failure.

    Conclusions:

    • Neurologists can use these recommendations to assess DMT effectiveness in MS patients.
    • The guidelines facilitate decisions on treatment modification to optimize outcomes.
    • These recommendations aim to improve the management of multiple sclerosis through better treatment monitoring.